Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma
-
Timmerman, John (UCLA Medical Center)
;
Herbaux, Charles (Centre Hospitalier Régional Universitaire de Lille) ;
Ribrag, Vincent (Institut Gustave Roussy (Villejuif, França)) ;
Zelenetz, Andrew D. (Memorial Sloan Kettering Cancer Center) ;
Houot, Roch (Unité dʼInvestigation Clinique) ;
Neelapu, Sattva S. (The University of Texas MD Anderson Cancer Center) ;
Logan, Theodore (Indiana University) ;
Lossos, Izidore S. (Sylvester Comprehensive Cancer Center) ;
Urba, Walter (Providence Cancer Center) ;
Salles, Gilles (Université de Lyon) ;
Ramchandren, Radhakrishnan (Karmanos Cancer Institute) ;
Jacobson, Caron (Harvard Medical School) ;
Godwin, John (Providence Cancer Center) ;
Carpio Segura, Cecilia del Carmen (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Lathers, Deanne (Bristol-Myers Squibb) ;
Liu, Yali (Bristol-Myers Squibb) ;
Neely, Jaclyn (Bristol-Myers Squibb) ;
Suryawanshi, Satyendra (Bristol-Myers Squibb) ;
Koguchi, Yoshinobu (Providence Cancer Center) ;
Levy, Ronald (Stanford University School of Medicine)
visitant ::
identificació
Subscriure's to this discussion. You will then receive all new comments by email.
